Featured Research

from universities, journals, and other organizations

Medication improves health of patients with pulmonary arterial hypertension, study suggests

Date:
November 17, 2009
Source:
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)
Summary:
A new study finds the health and exercise capacity of PAH patients improved after two years of treatment with ambrisentan.

In one of the few studies of the long-term effects of medication in the treatment of pulmonary arterial hypertension (PAH) disease, a team of researchers found the health and exercise capacity of PAH patients improved after two years of treatment with ambrisentan, according to a study published in the current edition of the Journal of the American College of Cardiology.

A research team led by Ronald Oudiz, MD, FACC, a principal investigator at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed), conducted a follow-up of the studies conducted for the Food and Drug Administration's approval of ambrisentan. The researchers found 383 PAH patients treated for two years with ambrisentan had sustained improvements in their exercise capacity. The team also found a low risk of death and clinical worsening from the disease among the PAH patients treated with ambrisentan for two years.

"These are promising findings for patients who suffer from pulmonary arterial hypertension, an often fatal disease of the pulmonary circulation," said Dr. Oudiz. "Physicians and patients with PAH should consider the use of ambrisentan as part of a long-term strategy for treatment of the disease."

PAH is a disease of the pulmonary circulation often afflicting younger women and is characterized by a progressive elevation in pulmonary vascular resistance that leads to right ventricular failure and premature death. Although the number of approved therapies for PAH has grown in the past 10 years, the disease remains rapidly progressive with a poor prognosis for most patients. Despite treatment, 25% to 50% of all patients with PAH will not survive beyond five years.

Ambrisentan is an orally active, once-daily medication currently approved for the treatment of PAH patients in the U.S. and other countries on the basis of two 12-week randomized, double-blind, placebo-controlled, multicenter efficacy trials. In these studies, the drug improved exercise capacity, along with other clinical indications of PAH disease severity, including clinical worsening.

Prior to their study, the researchers said most long-term PAH studies have focused primarily on exercise capacity and safety for up to one year, with very little description of clinical effectiveness of ambrisentan treatment.

The researchers in the current two-year study found that the two higher doses of the medication, 5 milligrams and 10 milligrams, provided a sustained benefit. The lower dosage used in the study, 2.5 milligrams, was less effective, the researchers said.


Story Source:

The above story is based on materials provided by Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed). Note: Materials may be edited for content and length.


Journal Reference:

  1. Oudiz et al. Long-Term Ambrisentan Therapy for the Treatment of Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2009; 54 (21): 1971 DOI: 10.1016/j.jacc.2009.07.033

Cite This Page:

Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed). "Medication improves health of patients with pulmonary arterial hypertension, study suggests." ScienceDaily. ScienceDaily, 17 November 2009. <www.sciencedaily.com/releases/2009/11/091117094939.htm>.
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed). (2009, November 17). Medication improves health of patients with pulmonary arterial hypertension, study suggests. ScienceDaily. Retrieved July 28, 2014 from www.sciencedaily.com/releases/2009/11/091117094939.htm
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed). "Medication improves health of patients with pulmonary arterial hypertension, study suggests." ScienceDaily. www.sciencedaily.com/releases/2009/11/091117094939.htm (accessed July 28, 2014).

Share This




More Health & Medicine News

Monday, July 28, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Trees Could Save More Than 850 Lives Each Year

Trees Could Save More Than 850 Lives Each Year

Newsy (July 27, 2014) A national study conducted by the USDA Forest Service found that trees collectively save more than 850 lives on an annual basis. Video provided by Newsy
Powered by NewsLook.com
Google's Next Frontier: The Human Body

Google's Next Frontier: The Human Body

Newsy (July 27, 2014) Google is collecting genetic and molecular information to paint a picture of the perfectly healthy human. Video provided by Newsy
Powered by NewsLook.com
What's To Blame For Worst Ebola Outbreak In History?

What's To Blame For Worst Ebola Outbreak In History?

Newsy (July 27, 2014) A U.S. doctor has tested positive for the deadly Ebola virus, as the worst-ever outbreak continues to grow. Video provided by Newsy
Powered by NewsLook.com
Losing Sleep Leaves You Vulnerable To 'False Memories'

Losing Sleep Leaves You Vulnerable To 'False Memories'

Newsy (July 27, 2014) A new study shows sleep deprivation can make it harder for people to remember specific details of an event. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins